Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
64 studies found for:    GS-7977
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
Condition: Hepatitis C
Interventions: Drug: TMC435;   Drug: PSI-7977 (GS7977);   Drug: Ribavirin
2 Completed Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
Conditions: Hepatitis C;   HIV
Intervention: Drug: GS-7977/GS- 5885 FDC
3 Completed
Has Results
GS-7977 With Ribavirin for Hepatitis C (SPARE)
Condition: Hepatitis C
Interventions: Drug: GS7977;   Drug: RBV
4 Completed Safety of Efficacy of Sofosbuvir (GS-7977) and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
Conditions: Recurrent Chronic Hepatitis C Virus;   Post Liver Transplant
Interventions: Drug: Sofosbuvir;   Drug: RBV
5 Active, not recruiting Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
6 Recruiting Combination Therapy for Chronic Hepatitis C Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: Fixed Dose GS-7977/GS-5885;   Drug: FDC with GS-9451;   Drug: FDC with GS-9669
7 Completed
Has Results
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
Condition: Hepatitis C
Interventions: Drug: SOF;   Drug: PEG;   Drug: RBV
8 Completed
Has Results
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
9 Completed
Has Results
Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
10 Completed
Has Results
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
11 Completed
Has Results
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
Conditions: Hepatitis C;   HIV
Interventions: Drug: SOF;   Drug: EFV/FTC/TDF;   Drug: EFV;   Drug: ZDV/3TC;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: DRV;   Drug: RAL;   Drug: PEG;   Drug: RBV
12 Completed
Has Results
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Conditions: Hepatitis C;   Human Immunodeficiency Virus
Interventions: Drug: SOF;   Drug: RBV
13 Completed
Has Results
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Condition: Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
14 Active, not recruiting Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Conditions: Hepatitis C;   Hepatocellular Carcinoma
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin
15 Active, not recruiting Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, 3, or 6 HCV Infection
Condition: Chronic Hepatitis C
Interventions: Drug: LDV/SOF FDC;   Drug: SOF;   Drug: RBV;   Drug: PEG;   Drug: GS-9669;   Drug: GS-5816
16 Active, not recruiting Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Conditions: Hepatitis C;   Cirrhosis;   Portal Hypertension;   With or Without Liver Decompensation
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin
17 Completed
Has Results
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
Condition: Chronic Hepatitis C Infection
Interventions: Drug: SOF;   Drug: RBV;   Drug: PEG;   Drug: LDV;   Drug: GS-9669;   Drug: LDV/SOF
18 Recruiting Comparison of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/GS-5816;   Drug: SOF;   Drug: RBV
19 Completed An Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Subjects With Nosocomial Genotype 1 HCV Infection.
Condition: Hepatitis C
Intervention: Drug: LDV/SOF
20 Active, not recruiting Sofosbuvir+RBV for 16 or 24 Weeks and Sofosbuvir+PEG+RBV for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
Condition: Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years